Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

20201,128 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: The Lancet

Volume 396, Issue 10253, pp. 759-769

Field-Weighted Citation Impact: 72.60